Bluebird Bio Inc Stock Price, News & Analysis

bluebird bio completed the tax-free spin-off of its oncology programs into 2seventy bio, focusing on gene therapies for severe genetic diseases. The company has three near-term programs targeting sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy. It plans to host a spotlight investor call on November 18, 2021, regarding its bb1111 candidate for sickle cell disease. bluebird bio has submitted a biologics licensing application for betibeglogene autotemcel and anticipates a BLA for elivaldogene autotemcel by the end of 2021.

bluebird bio, Inc. (NASDAQ: BLUE) announced that October 19, 2021, will be the record date for the dividend distribution of 2seventy bio, Inc. shares to bluebird stockholders, marking the separation of the two companies. Each stockholder will receive one share of 2seventy for every three shares of bluebird held. The distribution will occur on or about November 4, 2021. The SEC has declared 2seventy’s Registration Statement effective, detailing the tax-free spin-off of bluebird's oncology programs. Expected trading for 2seventy will begin on October 18, 2021, under the symbol 'TSVT'.

bluebird bio has announced a tax-free spin-off of its oncology programs into 2seventy bio, with a completion timeline of early November 2021. Shareholders will receive 1 share of 2seventy bio for every 3 shares of bluebird bio owned. The company expects approximately $1.0B in cash reserves at the time of separation, funding 2seventy bio with $480M. Two new board members, Najoh Tita-Reid and Sarah Glickman, have been appointed to strengthen leadership. The separation is designed to enhance operational focus and shareholder value.

bluebird bio has completed a rolling submission of its Biologics License Application (BLA) to the FDA for betibeglogene autotemcel (beti-cel) gene therapy targeting transfusion-dependent β-thalassemia (TDT). This therapy, if approved, will be the first of its kind in the U.S. for TDT patients. The BLA is supported by data from Phase 1/2 and Phase 3 studies, covering over 220 patient-years. Notably, 89% of evaluable patients achieved transfusion independence. The submission reflects bluebird bio's commitment to advancing gene therapies for severe genetic diseases.

2seventy bio, the upcoming oncology spin-off from bluebird bio (NASDAQ: BLUE), has announced a series of investor events to discuss its research pipeline and strategic direction. The first session, scheduled for September 21, 2021, will focus on AML [DARIC33] and their next-gen multiple myeloma strategy. The second session will take place on September 22, 2021, highlighting bNHL [bbT369] and solid tumor strategies. Investors can access live webcasts and recordings for 90 days post-event via the bluebird bio website.

bluebird bio announced a $75 million private placement of common stock and equivalents to fund ongoing R&D and commercialization efforts for itself and upcoming independent company 2seventy bio. The separation is scheduled for October 2021, with an additional $900 million cash expected at that time. Completion of the placement hinges on customary conditions, with closing anticipated in September 2021.

bluebird bio announces key appointments and upcoming investor events ahead of its planned separation, targeted for mid-October 2021. Gina Consylman joins as Chief Financial Officer, bringing over 25 years of expertise, while Marcela Maus is appointed to the board of directors, enhancing the leadership team. Investor conferences will occur in September, featuring participation from both bluebird bio and 2seventy bio.

bluebird bio (NASDAQ: BLUE) reported its Q2 2021 results, revealing a net loss of $241.7 million, a significant increase compared to $21.5 million from Q2 2020. Total revenues plummeted to $7.5 million from $198.9 million year-over-year, largely due to adjustments from a prior BMS contract. The FDA has placed a clinical hold on the eli-cel gene therapy program, affecting timelines for its submission. However, the company remains on track with its ABECMA launch, generating $24 million in U.S. revenues and anticipates cash reserves of approximately $900 million post-separation of its businesses, expected by year-end 2021.

bluebird bio, Inc. (NASDAQ: BLUE) will report its Q2 2021 financial results on August 9, 2021, followed by a conference call at 8 a.m. ET. Investors can access the call by dialing (844) 825-4408 or +1 (315) 625-3227 for international calls. The company will also participate in the Wedbush PacGrow Healthcare Conference on August 11 at 12:00 p.m. ET. bluebird bio focuses on gene therapies for severe genetic diseases and cancer, aiming to provide treatment options for patients with critical needs.